Global estimates on the reports of vaccine‐associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Sooji Lee und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Myocarditis, Pericarditis, Pharmacovigilance, World Health Organization. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Due to the limitation of previous studies examining adverse reports of myocarditis and pericarditis associated with vaccines other than the COVID‐19 vaccine, there are challenges in establishing a comprehensive understanding of vaccine safety on a global scale. Hence, the objective of this study was to examine the worldwide burden of vaccine‐associated pericarditis and myocarditis and the vaccines associated with these indications. This study utilized the World Health Organization international pharmacovigilance database, from which records of vaccine‐associated pericarditis and myocarditis between 1969 and 2023 were extracted (over 130 million reports). We calculated global reporting counts, reported odds ratios (RORs), and information components (ICs) to discern the association between 19 vaccines and the occurrence of pericarditis and myocarditis across 156 countries and territories. We identified 49 096 reports (male, n = 30 013) of vaccine‐associated pericarditis and myocarditis among 73 590 reports of all‐cause pericarditis and myocarditis. There has been a significant increase in reports of vaccine‐related cardiac adverse events over time, with a noteworthy surge observed after 2020, attributed to cases of pericarditis associated with COVID‐19 mRNA vaccines. Smallpox vaccines were associated with most pericarditis and myocarditis reports (ROR: 73.68 [95% CI, 67.79–80.10]; IC [IC 0.25 ]: 6.05 [5.91]), followed by COVID‐19 mRNA vaccine (37.77 [37.00–38.56]; 3.07 [3.05]), anthrax vaccine (25.54 [22.37–29.16]; 4.58 [4.35]), typhoid vaccine (6.17 [5.16–7.38]; 2.59 [2.29]), encephalitis vaccine (2.00 [1.48–2.71]; 0.99 [0.47]), influenza vaccine (1.87 [1.71–2.04]; 0.90 [0.75]), and Ad5‐vectored COVID‐19 vaccine (1.40 [1.34–1.46]; 0.46 [0.39]). Concerning age and sex‐specific risks, reports of vaccine‐associated pericarditis and myocarditis were more prevalent among males and in older age groups. The age group between 12 and 17 years exhibited significant sex disproportion. Most of these adverse events had a short time to onset (median time: 1 day) and fatality rate was 0.44%. Our analysis of global data revealed an increase in pericarditis and myocarditis reports associated with vaccines, particularly live vaccines like smallpox and anthrax, notably in young males. While these adverse events are generally rare and mild, caution is warranted, especially for healthcare workers, due to potential myocardial injury‐related in‐hospital mortality. Further study with validated reporting is crucial to enhance accuracy in evaluating the correlation between vaccines and cardiac conditions for preventive measures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
- Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
- Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.
- Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Dong Keon Yon
Förderung
- National Research Foundation of Korea
Zitieren
APA
Lee, S., Jo, H., Lee, H., Lee, H., Lee, J., Kim, H. J., Kang, J., Jacob, L., Smith, L., Rahmati, M., López Sánchez, G. F., Dragioti, E., Jeon, H., Cho, J. M., Choi, Y., Park, J., Woo, S., & Yon, D. K. (2024). Global estimates on the reports of vaccine‐associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database. Journal of Medical Virology. https://doi.org/10.1002/jmv.29693
Vancouver
Lee S, Jo H, Lee H, Lee H, Lee J, Kim HJ, et al. Global estimates on the reports of vaccine‐associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database. Journal of Medical Virology. 2024. doi:10.1002/jmv.29693
BibTeX
@article{Lee2024,
author = {Lee, Sooji and Jo, Hyesu and Lee, Hyeri and Lee, Hayeon and Lee, Jinseok and Kim, Hyeon Jin and Kang, Jiseung and Jacob, Louis and Smith, Lee and Rahmati, Masoud and López Sánchez, Guillermo F and Dragioti, Elena and Jeon, Hongki and Cho, Jin-Man and Choi, Yujin and Park, Jaeyu and Woo, Selin and Yon, Dong Keon},
title = {Global estimates on the reports of vaccine‐associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29693}
}
EUVIMED